Your participation in the STRIVE Study is bringing Sarah Cannon, GRAIL, and its collaborators one step closer to developing an important new tool to detect cancer early. Thank you for completing the first phase of your STRIVE Study participation. Your continued engagement in the follow-up phase will help with the continued development of the GRAIL blood test.
The success of the STRIVE Study depends on our ability to follow participants for cancer events over time. This follow-up is critical to the development of a blood test for the early detection of cancer. The STRIVE Study team will be reaching out to participants occasionally to collect study follow-up information. Additionally, study researchers will also be actively monitoring electronic health records for up to 5 years from enrollment to capture clinical outcome data, including cancer diagnoses.
Sarah Cannon participants will be contacted with instructions for how to access and complete study follow-up activities. Study follow-up will take about 5 minutes of your time and can be completed on a computer, smartphone, or tablet with internet access. Participants may receive a mailed letter or phone call if they cannot be reached through email. If you have questions about study follow-up, please contact the Sarah Cannon STRIVE Study team by emailing email@example.com or by calling 1-833-I-STRIVE (1-833-478-7483).
Keeping your contact information up to date is very important so that the study team at your health center can reach you during the follow-up period. Please contact the study team by emailing firstname.lastname@example.org or by calling 1-833-I-STRIVE (1-833-478-7483) if:
● Your contact information changes
● You receive a cancer diagnosis, or
● You receive cancer care outside of the Sarah Cannon health system